Atara Biotherapeutics, Inc.
A biotechnology company making "off-the-shelf" T-cell therapies that treat cancer, autoimmune diseases, and viral infections, using cells donated by healthy strangers rather than a patient's own cells—so treatment can be delivered in days instead of weeks. Founded in 2012 by Dr. Isaac Ciechanover, the company is named in memory of his mother, Atara, who died of ovarian cancer; the name means "crown" in Hebrew. The technology grew out of research at Memorial Sloan Kettering Cancer Center and Australia's QIMR Berghofer Medical Research Institute.
Granted 307.9K · Bought 74.3K · Sold 394.0K
Granted 109.0K
Bought 248.2K
Granted 846.5K · Sold 809.9K
Granted 12.0K
Granted 75.6K
Bought 507.4K
Granted 71.0K · Bought 13.1K · Sold 92.6K
Granted 109.0K · Bought 454.3K
Granted 278.6K · Sold 243.1K
Granted 340.0K · Sold 49.2K
Granted 139.7K · Sold 19.0K
Granted 436.3K · Sold 111.0K
Granted 245.4K · Bought 2.0K · Sold 72.8K
Granted 135.6K · Bought 34.4K · Sold 761
Sold 19.3K
Granted 801.1K · Sold 106.9K
Granted 225.7K · Sold 105.6K
Granted 319.7K · Sold 189.6K
Granted 327.8K · Sold 196.6K
Granted 90.0K
Granted 2.20M · Sold 356.5K
Granted 98.4K · Sold 24.4K
Granted 69.6K
Granted 509.1K · Sold 67.0K
Granted 20.3K · Sold 10.3K
Granted 43.5K
Granted 24.0K
Granted 278.8K · Bought 100.0K
Granted 349.6K · Bought 299.2K · Sold 65.1K
Granted 55.1K · Sold 23.8K
Granted 31.5K
Granted 304.5K · Sold 25.6K
Granted 778.9K · Sold 95.9K
Granted 450.0K · Sold 39.3K
Granted 246.3K
Granted 235.3K
Bought 1.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| KPCB XV Associates, LLC +2 co-filers10% owner · 6 transactions | — | 4.88Mas of May 2015 | — | — | — |
| Huang James +1 co-filerDirector, 10% owner, 10% owner · 8 transactions | — | 3.27M | 307.9K | 74.3K | 394.0K |
| Seidenberg Beth CDirector · 23 transactions | — | 1.99Mas of Jun 2023 | 109.0K | — | — |
| Cadeddu John J. +7 co-filers10% owner · 2 transactions | — | 1.91Mas of Oct 2014 | — | — | — |
| Blair James C +6 co-filers10% owner · 2 transactions | — | 1.89Mas of Oct 2014 | — | 248.2K | — |
| Ciechanover Isaac E.Chief Executive Officer, Director · 347 transactions | — | 1.30Mas of May 2019 | 846.5K | — | 809.9K |
| Ciongoli Gregory AustinDirector, 10% owner, See Remarks · 1 transaction | — | 1.22M | 12.0K | — | — |
| Adiumentum Capital Fund I GP LLC +2 co-filersDirector, 10% owner, See remarks · 1 transaction | — | 1.21Mas of May 2025 | 75.6K | — | — |
| EcoR1 Capital, LLC10% owner · 1 transaction | — | 1.04M | — | 507.4K | — |
| Marcus Joel SDirector · 13 transactions | — | 899.9Kas of Mar 2019 | 71.0K | 13.1K | 92.6K |
| Dobmeier EricDirector · 12 transactions | — | 563.3Kas of Nov 2023 | 109.0K | 454.3K | — |
| Haqq ChristopherEVP, R&D & Chief Scientific Of · 73 transactions | — | 291.9Kas of Feb 2019 | 278.6K | — | 243.1K |
| Dupont JakobEVP, Head of R&D · 21 transactions | — | 290.8Kas of Mar 2023 | 340.0K | — | 49.2K |
| Banard Charlene A.EVP, Chief Technical Officer · 2 transactions | — | 276.0Kas of May 2023 | 139.7K | — | 19.0K |
| Soffer GadEVP & Chief Strategy Officer · 57 transactions | — | 244.0Kas of Sep 2018 | 436.3K | — | 111.0K |
| Koppikar UtpalChief Financial Officer · 31 transactions | — | 182.0Kas of Mar 2023 | 245.4K | 2.0K | 72.8K |
| Yarema KristinChief Commercial Officer · 7 transactions | — | 171.4Kas of Mar 2022 | 135.6K | 34.4K | 761 |
| Joshi ManherEVP, Chief Medical Officer · 3 transactions | — | 171.3Kas of Nov 2023 | — | — | 19.3K |
| Nguyen AnhCoPresident and CEO, Director · 25 transactions | — | 132.8K | 801.1K | — | 106.9K |
| Newell JoeChief Operations Officer · 67 transactions | — | 113.1Kas of Nov 2021 | 225.7K | — | 105.6K |
| Clark Mitchall G.EVP & Chief R & QA Officer · 45 transactions | — | 108.0Kas of May 2018 | 319.7K | — | 189.6K |
| McGrath JohnEVP & Chief Financial Officer · 57 transactions | — | 88.8Kas of Mar 2018 | 327.8K | — | 196.6K |
| Berger DietmarGlobal Head of R&D · 4 transactions | — | 85.7Kas of May 2019 | 90.0K | — | — |
| Touchon PascalDirector · 32 transactions | — | 78.0Kas of Jun 2025 | 2.20M | — | 356.5K |
| Turner Heather DFormer EVP, GC & Sec. · 11 transactions | — | 73.0Kas of Feb 2018 | 98.4K | — | 24.4K |
| Kim MinaSenior VP & General Counsel · 4 transactions | — | 66.4Kas of Apr 2019 | 69.6K | — | — |
| Hyllengren Eric JEVP, CFO and COO · 14 transactions | — | 56.2Kas of Mar 2025 | 509.1K | — | 67.0K |
| Grant-Huerta YaninaChief Accounting Officer · 13 transactions | — | 49.6K | 20.3K | — | 10.3K |
| Baynes Roy D.Director · 4 transactions | — | 43.5Kas of Jun 2022 | 43.5K | — | — |
| Cherry Brian NDirector · 1 transaction | — | 38.3K | 24.0K | — | — |
| Heiden William KDirector · 12 transactions | — | 34.2K | 278.8K | 100.0K | — |
| Gallagher Carol GiltnerDirector · 65 transactions | — | 33.0Kas of Jun 2025 | 349.6K | 299.2K | 65.1K |
| Porter DerrellSVP, Head of Global Commercial · 9 transactions | — | 31.7Kas of Mar 2019 | 55.1K | — | 23.8K |
| Renaud Ronald C JRDirector · 2 transactions | — | 31.5Kas of Jun 2022 | 31.5K | — | — |
| Fust Matthew KDirector · 26 transactions | — | 30.2K | 304.5K | — | 25.6K |
| Murugan AmarEVP, Chief Legal Officer · 26 transactions | — | 26.9Kas of Aug 2024 | 778.9K | — | 95.9K |
| Henrich JillEVP, Chief Regulatory Officer · 10 transactions | — | 18.7Kas of Mar 2025 | 450.0K | — | 39.3K |
| Roncarolo Maria GraziaDirector · 5 transactions | — | 17.4Kas of Jun 2025 | 246.3K | — | — |
| Mallik AmeetDirector · 4 transactions | — | 16.9Kas of Jun 2025 | 235.3K | — | — |
| Blair James C +6 co-filers10% owner · 2 transactions | — | 14.0Kas of Oct 2014 | — | 1.8K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.38M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.